My colleague Andrew Rouse asks what the Number-needed-to-treat (NNT)
might be for oseltamivir. Smith & Dutkowski 'clarify' the data on
improved mortality by quoting relative risk reductions. The web- site
(www.eswi.org) they reference does not give the data needed to calculate
NNTs, either. It is co-sponsored by Roche. Is there something to hide?
Competing interests:
REF provides advice on Therapeutics to Public Health Physicians in Birmingham.
Competing interests:
No competing interests
24 November 2005
Robin Esmond Ferner
Director
West Midlands Centre for Adverse Drug Reaction Reporting
Rapid Response:
Stockpiling oseltamivir: not the NNT
My colleague Andrew Rouse asks what the Number-needed-to-treat (NNT)
might be for oseltamivir. Smith & Dutkowski 'clarify' the data on
improved mortality by quoting relative risk reductions. The web- site
(www.eswi.org) they reference does not give the data needed to calculate
NNTs, either. It is co-sponsored by Roche. Is there something to hide?
Competing interests:
REF provides advice on Therapeutics to Public Health Physicians in Birmingham.
Competing interests: No competing interests